BioCardia CEO buys 800 shares at $1.09 each

BioCardia’s CEO reported a small open-market share purchase, bringing his direct holdings to 381,985 shares after a correction of prior reporting.

Rhea-AI Filing Summary

BioCardia, Inc. (BCDA) reported that President and CEO Peter Altman purchased 800 shares of common stock in a direct, open-market transaction on September 3, 2026, at a weighted average price of $1.09 per share, with individual trade prices ranging from $1.09 to $1.10. Following this purchase and a correction adding 70 previously omitted shares, he directly holds 381,985 shares of BioCardia common stock.

Insider Trade Summary

Net Buyer: 800 shares

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 800 shs ($872.00)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2	800	$1.09	$872.00

Holdings After Transaction: Common Stock — 381,985 shares (Direct)

Footnotes (2)

1. F1. This transaction was executed in multiple trades ranging from $1.09 to $1.10 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.
2. F2. The total herein has been corrected by adding 70 shares that were inadvertently omitted from the Form 4 filed August 18, 2026.

Key Figures

Shares purchased: 800 shares Weighted average purchase price: $1.09 per share Shares owned after transaction: 381,985 shares +2 more

5 metrics

Shares purchased 800 shares Common stock bought on September 3, 2026

Weighted average purchase price $1.09 per share Open-market transaction on September 3, 2026; trades ranged $1.09–$1.10

Shares owned after transaction 381,985 shares Direct holdings of Peter Altman following the reported purchase and correction

Correction to prior Form 4 70 shares Additional shares added that were omitted from Form 4 filed August 18, 2026

Net insider share change 800 shares increase Net buy shares reported in transaction summary

Key Terms

weighted average per share sales price, open market or private transaction, Form 4

3 terms

weighted average per share sales price financial

"The price reported above reflects the weighted average per share sales price"

open market or private transaction market

"Purchase in open market or private transaction"

Form 4 regulatory

"omitted from the Form 4 filed August 18, 2026"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioCardia (BCDA) report on this Form 4?

The filing reports that President and CEO Peter Altman purchased 800 shares of BioCardia common stock in a direct, open-market transaction on September 3, 2026.

At what price did the BioCardia (BCDA) CEO buy the 800 shares?

Peter Altman’s 800-share purchase was executed in multiple trades between $1.09 and $1.10 per share. The Form 4 reports a $1.09 weighted average price per share for the transaction.

How many BioCardia (BCDA) shares does the CEO own after this transaction?

After the reported purchase and a prior-share correction, Peter Altman directly holds 381,985 shares of BioCardia common stock, as stated in the Form 4’s post-transaction holdings field.

Was the BioCardia (BCDA) CEO’s share purchase under a Rule 10b5-1 plan?

No. The Form 4’s Rule 10b5-1 checkbox is not marked, and the footnotes do not describe any Rule 10b5-1 trading plan, so no trading plan is reported for this transaction.

What correction to prior BioCardia (BCDA) reporting is disclosed in this Form 4?

A footnote states the total share holdings were corrected by adding 70 shares that were inadvertently omitted from a Form 4 filed on August 18, 2026, and that correction is reflected in the current total.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 09:31 PM EDT Accepted by SEC EDGAR 09/04/2026 - 09:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		P		800(1)	A	$1.09(1)	381,985(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $1.09 to $1.10 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

2. The total herein has been corrected by adding 70 shares that were inadvertently omitted from the Form 4 filed August 18, 2026.

	/s/ Peter Altman	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)